Fig. 7: scHRMCA data and HIV susceptibility of CCR5-edited CD4+ T cells.
From: Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application
Primary human CD4+ T cells from three different donors (#9–#11) were electroporated with 2.5 μg of CCR5-Uco-hetTALEN_polyA L + R mRNA per 1 × 106 cells or without mRNA. a scHRMCA results showing wildtype (WT, grey), mono- (pink) and biallelic (blue) gene editing at the CCR5 locus, as well as the percentage of homologous (hom., dark blue) and heterologous (het., light blue) biallelic editing. b HIV infection assay with pseudotyped lentiviral vectors LeGO-GALVenv and LeGO-HIVenv simultaneously. Measurement of fluorescent positive cells was performed by flow cytometry. Bar graph shows HIVenv positive cells normalized to GALVenv positive cells for donor #9 (blue), #10 (pink) and #11 (green) for CCR5-edited (treated) and non-edited (mock) cells.
